01
前言
01
前言
02
什么是CIK细胞疗法
03
CP组合,疗效如何
04
CP组合,毒副如何
05
CP组合-肺癌免疫联合新思路
1. Hui Z, Zhang X, Ren B, et al. Rapid response ofadvanced squamous non-small cell lung cancer with thrombocytopenia afterfirst-line treatment with pembrolizumab plus autologous cytokine-induced killercells[J]. Front Immunol, 2015, 6: 633.
2. Han Y, Mu D, Liu T, et al. Autologouscytokine-induced killer (CIK) cells enhance the clinical response to PD-1blocking antibodies in patients with advanced non-small cell lung cancer: Apreliminary study[J]. Thoracic Cancer. 2020 Nov. DOI: 10.1111/1759-7714.13731.
3. 杨海南, 孙元元, 伍江平等. 抗PD-1单克隆抗体联合CIK细胞对肺癌细胞株杀伤作用的研究[J]. 现代肿瘤医学, 2019, 27(12): 2079-2083.
精彩推荐:
- End -